FDA Approves Tepmetko (tepotinib) for NSCLC with MET Exon 14 Skipping Mutations
On February 3rd, 2021, the Food and Drug Administration (FDA) approved Tepmetko (tepotinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET called exon 14 skipping. The FDA based their approval on the results of [...]